Loading
companiesCompany
Enlaza Therapeutics
Enlaza Therapeutics engineers protein drugs that lock permanently onto their target once they find it, which could let antibody-based cancer medicines work at lower doses with fewer side effects. Its programmes are still in laboratory development.
Overview
Enlaza Therapeutics (La Jolla, California) is building the first covalent biologic platform. Its War-Lock technology introduces proprietary unnatural amino acids into protein therapeutics so that they bind irreversibly to disease-relevant targets while remaining latent until target engagement, with the aim of improving efficacy and reducing toxicity for antibody-drug conjugates, T-cell engagers and other protein drugs, initially in oncology. The pipeline is preclinical and undisclosed. The company launched in December 2022 with USD 61 million in seed financing led by Avalon Ventures and raised a USD 100 million Series A in April 2024 led by the Life Sciences group of J.P. Morgan Private Capital, with Amgen Ventures and Regeneron Ventures among new investors. In September 2025 it announced a strategic collaboration with Vertex Pharmaceuticals to develop War-Lock drug conjugates and T-cell engagers for conditioning and certain autoimmune diseases.
Headquarters
La Jolla, CA, US
Funding
All startupsStartup
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Led by the Life Sciences group of J.P. Morgan Private Capital | 2024 | $100M | enlazatx.com |
| Seed · Led by Avalon Ventures | 2022 | $61M | enlazatx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- The website blocks scripted curl requests (Cloudflare) but was fetched via WebFetch; press release pages fetched directly. The Vertex collaboration is outside oncology.
Similar pages
- CompanyAlpha-9 Oncology
Shares Samsara BioCapital, Lightspeed Venture Partners, Frazier Life Sciences.
- CompanyDantari
Shares Alexandria Venture Investments, Antibody-drug conjugate (ADC).
- IdeaAn open engineering platform for academic ADCs and bispecifics
Shares Site-specific conjugation & linker chemistry, T-cell engagers (bispecific), Antibody-drug conjugate (ADC).
- CompanyPheon Therapeutics
Shares Lightspeed Venture Partners, Antibody-drug conjugate (ADC).
- TechnologyAntibody-oligonucleotide conjugates
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TrialARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TermDrug-to-antibody ratio (DAR)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- CompanySynaffix (Lonza)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).